The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons
- PMID: 19907191
- PMCID: PMC2857623
- DOI: 10.1159/000256662
The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons
Abstract
Background: The apolipoprotein E (APOE) epsilon4 allele is a well-known risk factor for the development of Alzheimer's disease, but little is known about the association of the epsilon4 allele with incident mild cognitive impairment (MCI).
Objective: Test the hypothesis that the epsilon4 allele is associated with an increased risk of developing MCI.
Methods: More than 600 older Catholic clergy members from the Religious Orders Study without any cognitive impairment at baseline underwent APOE genotyping and detailed annual clinical evaluations for up to 16 years of follow-up (mean: 10.17 years; range: 2-16 years) to document incident MCI and rates of decline in global cognition and 5 cognitive domains (i.e. episodic memory, semantic memory, working memory, perceptual speed and visuospatial abilities).
Results: During up to 16 years of annual follow-up, 339 of 607 persons (56%) developed MCI. In a proportional hazards model adjusted for age, sex and education, the presence of the APOE epsilon4 allele was associated with a 1.4-fold increased risk of incident MCI (hazard ratio: 1.36; 95% CI: 1.04, 1.78). Further, this association persisted in analyses that required MCI to persist for at least one year (hazard ratio: 1.50; 95% CI: 1.05, 2.14). Finally, the epsilon4 allele was associated with an increased rate of decline in global cognition and 4 out of 5 cognitive systems (i.e. episodic memory, semantic memory, working memory and perceptual speed).
Conclusion: The presence of the APOE epsilon4 allele is associated with an increased risk of MCI and a more rapid rate of cognitive decline in old age.
2009 S. Karger AG, Basel.
Figures


Similar articles
-
The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.Neurocase. 2005 Feb;11(1):3-7. doi: 10.1080/13554790490903038. Neurocase. 2005. PMID: 15804918
-
Association between apolipoprotein E ε4 and longitudinal cognitive decline: nested case-control study among chinese community-dwelling elders.Neuropsychobiology. 2011;64(2):102-9. doi: 10.1159/000324991. Epub 2011 Jun 21. Neuropsychobiology. 2011. PMID: 21701228
-
APOE ε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan.J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):165-9. doi: 10.1136/jnnp.2010.209122. Epub 2010 Jul 26. J Neurol Neurosurg Psychiatry. 2011. PMID: 20660919
-
Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease.Neurology. 2003 Jan 28;60(2):246-52. doi: 10.1212/01.wnl.0000042478.08543.f7. Neurology. 2003. PMID: 12552039
-
Sleep apnea, apolipoprotein epsilon 4 allele, and TBI: mechanism for cognitive dysfunction and development of dementia.J Rehabil Res Dev. 2009;46(6):837-50. doi: 10.1682/jrrd.2008.10.0140. J Rehabil Res Dev. 2009. PMID: 20104407 Review.
Cited by
-
Kai Xin San ameliorates scopolamine-induced cognitive dysfunction.Neural Regen Res. 2019 May;14(5):794-804. doi: 10.4103/1673-5374.249227. Neural Regen Res. 2019. PMID: 30688265 Free PMC article.
-
In Thai Nationals, the ApoE4 Allele Affects Multiple Domains of Neuropsychological, Biobehavioral, and Social Functioning Thereby Contributing to Alzheimer's Disorder, while the ApoE3 Allele Protects Against Neuropsychiatric Symptoms and Psychosocial Deficits.Mol Neurobiol. 2018 Aug;55(8):6449-6462. doi: 10.1007/s12035-017-0848-0. Epub 2018 Jan 6. Mol Neurobiol. 2018. PMID: 29307083
-
APOE influences working memory in non-demented elderly through an interaction with SPON1 rs2618516.Hum Brain Mapp. 2018 Jul;39(7):2859-2867. doi: 10.1002/hbm.24045. Epub 2018 Mar 24. Hum Brain Mapp. 2018. PMID: 29573041 Free PMC article.
-
Association of APOE with tau-tangle pathology with and without β-amyloid.Neurobiol Aging. 2016 Jan;37:19-25. doi: 10.1016/j.neurobiolaging.2015.09.011. Epub 2015 Sep 28. Neurobiol Aging. 2016. PMID: 26481403 Free PMC article.
-
Mild Cognitive Impairment and Susceptibility to Scams in Old Age.J Alzheimers Dis. 2016;49(3):845-51. doi: 10.3233/JAD-150442. J Alzheimers Dis. 2016. PMID: 26519434 Free PMC article.
References
-
- Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594–1599. - PubMed
-
- Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179–1184. - PubMed
-
- Morris JC. Mild cognitive impairment is early-stage Alzheimer disease. Arch Neurol. 2006;63:15–16. - PubMed
-
- Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205. - PubMed
-
- Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006;67:441–445. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous